ITeos And GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug And Dostarlimab In Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer; Primary Endpoints Of The Trial Are Progression...
ITeos And GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug And Dostarlimab In Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer; Primary Endpoints Of The Trial Are Progression...
ITeos和GSK啓動GALAXIES肺-301第3期研究，評估Belrestotug和Dostarlimab在未接受治療、不可切除的PD-L1選擇非小細胞肺癌晚期/轉移性患者中的應用；該試驗的主要終點是疾病進展...
ITeos And GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug And Dostarlimab In Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer; Primary Endpoints Of The Trial Are Progression Free Survival And Overall Survival
iTeos和GSK發起GALAXIES Lung-301第3期研究，評估Belrestotug和Dostarlimab在PD-L1陽性未手術切除的晚期/轉移性非小細胞肺癌中的應用；本次試驗的主要終點是無進展生存期和總生存期。
iTeos Therapeutics, Inc. (NASDAQ:ITOS) ("iTeos"), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, and its development partner GSK, have initiated the first, global Phase 3 registration study of belrestotug + dostarlimab doublet versus placebo + pembrolizumab in patients with previously untreated, unresectable, locally advanced or metastatic PD-L1 selected non-small cell lung cancer (NSCLC).
iTeos Therapeutics, Inc.（NASDAQ：ITOS）（“iTeos”）是一家臨床階段生物製藥公司，專注於爲患者開發和創新下一代免疫腫瘤治療藥物。該公司及其開發夥伴GSK已啓動全球首個第3期註冊研究，以Belrestotug+ Dostarlimab雙聯療法與安慰劑+ 皮瑞巴利單抗治療PD-L1陽性未手術切除的晚期/轉移性非小細胞肺癌患者。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。